11/4/2026

speaker
Conference Operator
Operator

Good day and welcome to the AAR Surgical third quarter 2026 results call and webcast. During today's presentation, all parties will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touchstone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the call over to Connie Johnson, Director of Investor Relations. Please go ahead.

speaker
Connie Johnson
Director of Investor Relations

Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, President and Chief Executive Officer of AAR Surgical, and Deborah Andrews, Executive Vice President and Chief Financial Officer of AAR Surgical. Earlier today, we reported our third quarter 2026 results. We posted our results release and shareholder letter to our investor website at investors.aar.com. Today's call is scheduled for one hour and will include Q&A for publishing analysts. We also invite webcast participants to send questions to ir.star.com. Before we get started, during today's discussion, we will be making forward-looking statements. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Please read the disclosures in today's release and our SEC filings. Except as required by law, AAR assumes no obligation to update these statements to reflect future events or actual outcomes. We will also reference certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA per diluted share, free cash flow, and results excluding the China deferred sales. Please refer to today's release for additional information and applicable reconciliations to the most directly comparable GAAP measures. Unless otherwise specified, all comparisons will be year over year. Finally, we intend to use our investor website to disclose material nonpublic information and comply with Regulation FD. Please monitor that website along with our press releases, SEC filings, and public calls and webcasts. With that, I would like to turn the presentation over to Warren. Warren?

speaker
Warren Foust
President and Chief Executive Officer

Thank you, Connie. Good afternoon, everyone, and thank you for joining us. At the start of the year, we set three goals, revenue growth, profit expansion, and innovation acceleration. Through the first nine months, we've made progress on all three. Year-to-date, we delivered record revenue, achieved strong profitability, and took important steps toward bringing our next generation of products to patients. Our strong cash flow and debt-free balance sheet give us flexibility to keep investing in that future. I want to thank our teams in China and Japan, our two largest markets, as well as all of our dedicated employees in Switzerland and the United States and all around the world. This year, they implemented a new ERP system, completed the move of China-bound ICL manufacturing to Switzerland, ramped production to support the EVO Plus launch in China, and began the clinical trial process for two new lenses, all while continuing to serve surgeons and patients. That is a lot of change. and they have delivered and continue to do so, strengthening how we operate and laying further groundwork for future growth. Now, let's talk about where we stand. Let me start with revenue growth, which is being driven by an ongoing shift from lasers to lenses. With China being our largest market, let's go right there and spend a little time. In the third quarter, excluding the $25.9 million recognized in the third quarter 2025, revenue grew 31%. Distributor unit shipments in the China market grew 12.4% through the first nine months, a step up from mid-single-digit growth in 2025, outpacing the broader Chinese refractive market. We are encouraged that hundreds of mid-tier hospitals have begun to close the gap with our largest and longest-established centers, which continue to set the benchmark for ICL productivity and have recently publicly cited EvoPlus as a driver of their growth. Recent commentary from AAR provides one useful perspective. in reporting on its third quarter performance, AAR cited rising penetration of premium refractive procedures, including EVO Plus, as supporting a better procedure mix that is consistent with what we are seeing in EVO Plus adoption across China. Mix is helping us as well. Adoption of EVO Plus and toric lenses is raising our average selling prices, and because we were not yet able to fully meet the demand for lenses in the third quarter, all of our China net sales growth came from higher average selling prices. Our focus on ensuring proper inventory levels continues to pay off as well. In fact, distributor inventory has declined over the past four quarters to below our six-month target, while in-market unit volume shipments have grown. Alongside our inability to fully meet third quarter lens demand, this reinforces our focus on expanding manufacturing capacity. As available supply improves, we expect our shipments to our distributors to reflect underlying demand more closely. We are quite pleased with our progress in China. Globally, we delivered record revenue through the first nine months. Turning back to regional performance, Asia Pacific, excluding China, grew 4%. Revenue growth in India, Taiwan, and other markets was partly offset by a slight decline in Japan, primarily due to currency, and South Korea, primarily caused by overall market weakness. In EMEA, we grew 31%, or 51%, excluding the Middle East. Our growth was driven by strong double-digit growth in Spain, Germany, and the UK. We round out our global performance with the Americas, which put up 14% growth. Growth in the Americas was led by the US, where we posted our third consecutive quarter of greater than $6 million in sales. In the US, the opportunity is not only about gaining share within the existing refractive surgery market, it is about helping practices reach appropriate patients who have remained on the sidelines. Refractive Surgery Council data indicate that U.S. laser vision correction procedures have declined 5.8% in 2026 versus 2025, while our sales grew double digits. We believe the ongoing structural shift of the refractive surgery market from lasers to lenses is an important long-term growth driver. In September, we published our market report, The Future of Refractive Surgery, which shows the ongoing shift from laser-based to lens-based vision correction in multiple markets. Our consumer research shows that patients want freedom from glasses and contacts and that they place a high value on safety, choice, and reversibility. Our job is to help practices turn that interest into treatment. On profit, we continue making progress and there is more work to do. For the first three quarters, we have delivered record revenue, strong adjusted EBITDA, and free cash flow, and we remain debt free. Excluding the impact of the China deferred sales on the prior year comparison, We improved from an adjusted net loss in last year's third quarter to gap net income this quarter. Gross margin in the third quarter was affected by several temporary factors, including the ERP implementation, freight, tariffs, and inventory provisions. Looking ahead, we expect fourth quarter gross margin to be above the third quarter, and we expect gross margin to continue to improve in 2027 as unit costs improve with both our U.S. and our Swiss production facilities running at full capacity. Our operational priorities are clear. Improve product availability, increase manufacturing yields, and allocate capital where it offers the best return on shareholder investment. In September, our board authorized a $50 million share repurchase program, reflecting its confidence in the business and its belief that star shares are undervalued. We will continue to take a disciplined, returns-focused approach to capital allocation to maximize shareholder value creation over time. That brings me to our third goal, innovation acceleration. We are focused on innovating in three key areas. Of course, product innovation, but also commercial innovation as well as operational innovation. When we talk about product innovation, we're focused on the future of vision. Collimer is at the heart of what makes Evo different. With more than 30 years of clinical evidence, over 100,000 eyes studied, and more than 4 million lenses distributed worldwide, we believe that Evo ICL stands as the most clinically validated FACIC IOL in the world, giving us a strong foundation for expanding beyond our core offering. Ben Park, our recently appointed Chief Technology Officer, is leading our R&D team's work across a variety of therapeutic areas. Ben joined us a few months ago and is already making an impact. I'm excited about how his engineering, material science, and commercialization experience will help us harness Collimer's advantage to develop new products. We are approaching an important milestone. First in human trials for two columnar-based presbyopia products are expected to begin patient enrollment in the next few months, subject to the receipt of the remaining required regulatory authorizations. These studies are a tangible step from pipeline to patient. Our ambition is to build toward a meaningful product launch in a critical market every 18 to 24 months. It will take time to build that reality, but we are already on that journey, and I'm excited by the potential. Our commercial innovation strategy is clear. Make EVO-ICL a primary option for patients who want freedom from glasses and contacts. That means deeper adoption with surgeons already choosing EVO, expanding into lower diopters, and reaching new patients who are searching for freedom from glasses or contact lenses. To lead that effort, David Bailey, a former star CEO, returned in September as chief commercial officer. David built much of what our commercial engine is today, and he has a clear mandate to drive deeper surgeon adoption of Evo. That means better education, stronger evidence programs, smarter use of data, and more targeted patient awareness, market by market, and surgeon by surgeon. We also welcomed Andrew Pilon as Vice President of Business Development to expand strategic partnerships and our global footprint. Earlier this week, we appointed Pascal Ashleyman as Vice President of Asia Pacific. Pascal helped lead our expansion across Asia and the Middle East during his earlier tenure with Star. Recent label expansions raised US eligibility to age 60, adding approximately 8 million potentially eligible patients, and lowered Brazil's minimum prescription to minus 0.5 diopters adding an estimated 26 million potential patients. Our opportunity is to help appropriate, newly eligible patients access treatment. Finally, operational innovation is about delivering with excellence. We completed the operational transition that allows all China-bound ICLs to be manufactured in Switzerland, reducing our tariff exposure and strengthening supply chain resilience. DECRA certification for a second clean room at NEDOW supports our ability to scale further. We are improving manufacturing yields, expanding machining capacity at Monrovia, and evaluating automation while maintaining the rigorous quality standards required for columnar. Each percentage point of yield improvement could generate approximately $750,000 to $1 million in annual incremental gross profit. Building on our new ERP system, we are also strengthening supply chain planning and inventory management capabilities. Our work to strengthen the organization for future growth continues. With that, I will turn the call over to Deborah to walk through the financials. Deborah?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API